Home Tools
Log in
Cart

PLK

Polo-like kinase (PLK) is a highly conserved serine/threonine protein kinase with a highly homologous serine/threonine kinase domain at its N-terminus, which regulates PLK activity and subcellular dynamics at the C-terminus and targeted polo-box domain (PBD). There are many PLK family members, and there are four subtypes in the human body, namely PLK1, PLK2, PLK3, and PLK4, which play important roles in the regulation of various phases of the cell cycle.
Cat No. product name
T6217 LFM-A13 LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and...
T6173 BI 2536 BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3.
T6283 Wortmannin Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM, with little selectivity within the PI3K family. Also blocks autophagosome formation and poten...
T6019 Volasertib Volasertib (BI-6727) is a potent inhibitor of PLK1 (IC50: 0.87 nM), inducing mitotic arrest and apoptosis. It also inhibits PLK2/PLK3 (IC50s: 5/56 nM).
T5818 Rigosertib sodium Rigosertib, a non-ATP-competitive inhibitor of PLK1(IC50=9 nM), exhibits 30-fold higher specificity activity over Plk2 and no effect on Plk3.
T0973 Pyridoxine Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Although pyridoxine and vitamin B6 are still frequently us...
T16750 Rigosertib Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, which...
T19664 ON1231320 ON1231320 is a Polo-like kinase 2 (PLK2) inhibitor.
T1839 Mps1-IN-2 Mps1-IN-2 is a potent, selective and ATP-competitive dual Mps1/Plk1 inhibitor.
T6247 Onvansertib NMS-P937 (NMS1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over ...
T2271 SBE13 Hydrochloride SBE13 hydrochloride is an effective and specific PLK1 inhibitor (IC50: 0.2 nM); no inhibition om Aurora A kinase, Plk2/3.
T22288 (1E)-CFI-400437 dihydrochloride CFI-400437 dihydrochloride is a selective and potent polo-like kinase 4 (PLK4) inhibitor.
T2634 Ro3280 Ro3280 is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM).
T2704 MLN0905 MLN0905 is an effective PLK1 inhibitor(IC50=2 nM).
T2438 HMN-214 HMN-214(IVX214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.
T7384 CFI-400945 free base CFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM).
T7200 TAK-960 TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.
T8912 5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE 5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE targets PLK1.
TN3247 7-O-Prenylscopoletin 7-O-Prenylscopoletin and cedrelopsin show high antiproliferative activities against cancer cell lines.
T6282 GSK461364 GSK461364(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.
T6070 ON-01910 ON-01910 is a non-ATP-competitive PLK1 inhibitor(IC50 of 9 nM, in a cell-free assay). It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. ...
T6338 PHA-680632 PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGF...
T3643 HMN-176 HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1).
T17008 TC-S 7005 TC-S 7005 is an inhibitor of Polo-like kinases (IC50s: 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively).
T16560 Poloxin Poloxin is a non-ATP competitive Polo-like Kinase 1 inhibitor. It targets the polo-box domain (IC50: appr 4.8 μM).
T16559 Poloxime Poloxime is a hydrolysis product of poloxin and is a non-ATP-competitive Plk1 inhibitor. It also has moderate Plk1 inhibitory activity.
T14927 Centrinone Centrinone (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).
LFM-A13
T6217
LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR...
BI 2536
T6173
BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3.
Wortmannin
T6283
Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM, with little selectivity within the PI3K family. Also blocks autophagosome formation and poten...
Volasertib
T6019
Volasertib (BI-6727) is a potent inhibitor of PLK1 (IC50: 0.87 nM), inducing mitotic arrest and apoptosis. It also inhibits PLK2/PLK3 (IC50s: 5/56 nM).
Rigosertib sodium
T5818
Rigosertib, a non-ATP-competitive inhibitor of PLK1(IC50=9 nM), exhibits 30-fold higher specificity activity over Plk2 and no effect on Plk3.
Pyridoxine
T0973
Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Although pyridoxine and vitamin B6 are still frequently us...
Rigosertib
T16750
Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, which...
ON1231320
T19664
ON1231320 is a Polo-like kinase 2 (PLK2) inhibitor.
Mps1-IN-2
T1839
Mps1-IN-2 is a potent, selective and ATP-competitive dual Mps1/Plk1 inhibitor.
Onvansertib
T6247
NMS-P937 (NMS1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over ...
SBE13 Hydrochloride
T2271
SBE13 hydrochloride is an effective and specific PLK1 inhibitor (IC50: 0.2 nM); no inhibition om Aurora A kinase, Plk2/3.
(1E)-CFI-400437 dihydrochloride
T22288
CFI-400437 dihydrochloride is a selective and potent polo-like kinase 4 (PLK4) inhibitor.
Ro3280
T2634
Ro3280 is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM).
MLN0905
T2704
MLN0905 is an effective PLK1 inhibitor(IC50=2 nM).
HMN-214
T2438
HMN-214(IVX214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.
CFI-400945 free base
T7384
CFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM).
TAK-960
T7200
TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.
5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE
T8912
5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE targets PLK1.
7-O-Prenylscopoletin
TN3247
7-O-Prenylscopoletin and cedrelopsin show high antiproliferative activities against cancer cell lines.
GSK461364
T6282
GSK461364(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.
ON-01910
T6070
ON-01910 is a non-ATP-competitive PLK1 inhibitor(IC50 of 9 nM, in a cell-free assay). It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. ...
PHA-680632
T6338
PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGF...
HMN-176
T3643
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1).
TC-S 7005
T17008
TC-S 7005 is an inhibitor of Polo-like kinases (IC50s: 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively).
Poloxin
T16560
Poloxin is a non-ATP competitive Polo-like Kinase 1 inhibitor. It targets the polo-box domain (IC50: appr 4.8 μM).
Poloxime
T16559
Poloxime is a hydrolysis product of poloxin and is a non-ATP-competitive Plk1 inhibitor. It also has moderate Plk1 inhibitory activity.
Centrinone
T14927
Centrinone (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).